ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 179 filers reported holding ARCUS BIOSCIENCES INC in Q2 2022. The put-call ratio across all filers is 2.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,429,701 | -20.5% | 246,780 | -10.1% | 0.01% | -35.3% |
| Q2 2023 | $5,574,039 | +248.9% | 274,448 | +213.3% | 0.02% | +142.9% |
| Q1 2023 | $1,597,569 | +129.7% | 87,586 | +160.5% | 0.01% | +133.3% |
| Q4 2022 | $695,365 | +65.2% | 33,625 | +108.9% | 0.00% | +50.0% |
| Q3 2022 | $421,000 | -84.1% | 16,098 | -84.6% | 0.00% | -86.7% |
| Q2 2022 | $2,648,000 | -17.5% | 104,515 | +2.8% | 0.02% | +7.1% |
| Q1 2022 | $3,210,000 | +355.3% | 101,696 | +484.0% | 0.01% | +600.0% |
| Q4 2021 | $705,000 | -17.6% | 17,415 | -42.9% | 0.00% | -60.0% |
| Q1 2021 | $856,000 | -60.5% | 30,473 | -63.5% | 0.01% | -68.8% |
| Q4 2020 | $2,166,000 | +9.7% | 83,448 | -27.5% | 0.02% | -40.7% |
| Q3 2020 | $1,974,000 | -50.1% | 115,163 | -27.9% | 0.03% | -57.8% |
| Q2 2020 | $3,953,000 | +1533.5% | 159,799 | +568.3% | 0.06% | +6300.0% |
| Q4 2019 | $242,000 | – | 23,911 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |